Orexigen Up, Then Steeply Down Following Contrave U.S. Rights Agreement By: Benzinga via Benzinga March 15, 2016 at 12:10 PM EDT Orexigen Therapeutics, Inc. (NASDAQ: OREX) spiked almost 3 percent to $0.81 early Tuesday, but quickly plummeted more than 6 ... Read More >> Related Stocks: Takeda Pharma